Health Condition 1: C921- Chronic myeloid leukemia, BCR/ABL-positive
Conditions
Interventions
None listed
Sponsors
Jamia Hamdard
Eligibility
Inclusion criteria
Inclusion criteria: 1)Diagnosis of Ph positive CML patients in chronic phase (CP) . 2)Patients on imatinib or nilotinib first line therapy for minimum six month duration. 3)Patientâ??s age must be of greater than 18 years .
Exclusion criteria
Exclusion criteria: 1)Patients with a history of another primary malignancy that is clinical significant or requires active intervention. 2)Patients unwilling to give the informed consent or unable to comply with the protocol. 3)Patients who are on any antidepressants are also excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the rate of depression and its correlation with health related quality of life and adherence in CML patientsTimepoint: at least after receiving six months of treatment and at time of assessment | — |
Secondary
| Measure | Time frame |
|---|---|
| Study of association of depression with BDNF , IL17 , TNFα , CRP. Study of association of depression with adverse events & response rates to imatinib or nilotinibTimepoint: secondary parameters are different from primary outcomes , at least after six months of treatment and at the time of assessment | — |
Countries
India
Contacts
Public ContactPratibha Bhatia
Jamia Hamdard
Outcome results
None listed